Kairos Pharma Ltd（KAPA）資訊與事件KAPAKairos Pharma Ltd

Kairos Pharma Announces 1-for-7 Reverse Stock Split

Kairos Pharma announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7. The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET, with shares expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026 under the existing trading symbol "KAPA" and a new CUSIP number of 48301N203. In connection with the Reverse Stock Split, every seven shares of the company's common stock issued and outstanding immediately prior to the Effective Time will be automatically reclassified and combined into one share of common stock. No fractional shares of common stock will be issued as a result of the Reverse Stock Split. Instead, the Company will issue to holders of record who were entitled to a fraction of a share as a result of the Reverse Stock Split, a fraction of a share of common stock as is necessary to round up to the nearest whole share. For shares held through The Depository Trust Company, fractions of shares will be issued as is necessary to round up to the nearest whole share at the DTC participant level. Brokers, banks or other nominees holding shares in "street name" will be instructed to effect the Reverse Stock Split for their beneficial holders; however, such brokers, banks or other nominees may apply their own specific procedures for processing the Reverse Stock Split.

Kairos Pharma Announces Strategic Collaboration with Bayer

Kairos Pharma (KAPA) announced a strategic collaboration with Bayer (BAYRY) to evaluate Kairos Pharma's lead antibody ENV-105, a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer's XOFIGO in metastatic castration-resistant prostate cancer involving bone. "Drug resistance remains one of the greatest challenges in advanced prostate cancer, and XOFIGO, like many standard-of-care therapies, can lose efficacy over time," said John Yu, M.D., Kairos Pharma Chief Executive Officer. "ENV-105 has already demonstrated the ability to re-sensitize tumors to existing treatments with a strong safety profile, and this collaboration with Bayer represents a major milestone in our mission to deliver more durable and more effective treatment regimens for patients with metastatic prostate cancer."

Kairos Pharma Announces Interim Safety Data for ENV-105 Clinical Trial

Kairos Pharma announced interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 in combination with osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer, NSCLC. The data represent a milestone in Kairos Pharma's lead program: resensitizing patients who have acquired resistance to osimertinib, the global standard-of-care for EGFR-mutated NSCLC. With no serious adverse events observed across 13 treated patients to date from ENV-105 treatment, the safety profile supports continued progression toward an early efficacy readout.